Holdings of Decheng Capital LLC
11 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 99.9 % of the equity sleeve
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- US 100.0 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | US | 11 | 630.8M $ | 100.00 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | CG oncology Inc | 6,371,669 | 431.2M $ | |
| 2 | Nuvation Bio Inc | 25,954,439 | 111.3M $ | |
| 3 | Upstream Bio Inc | 2,724,868 | 24.5M $ | |
| 4 | Aclaris Therapeutics Inc | 4,041,736 | 15.2M $ | |
| 5 | Aardvark Therapeutics Inc | 3,917,299 | 14.8M $ | |
| 6 | Arcus Biosciences Inc | 477,819 | 10.3M $ | |
| 7 | Revolution Medicines Inc | 93,500 | 9.1M $ | |
| 8 | Equillium Inc | 4,447,308 | 8.9M $ | |
| 9 | Zentalis Pharmaceuticals Inc | 1,323,327 | 3.1M $ | |
| 10 | Krystal Biotech Inc | 7,300 | 1.9M $ | |
| 11 | Pyxis Oncology Inc | 326,810 | 477.1K $ |